News jeff 2018-05-31T11:46:02+00:00

News

TaiRx’s New Drug CVM-1118 Granted Orphan Drug Designation for Pancreatic Neuroendocrine Tumors (PNETs), Securing Seven Years of Market Exclusivity in the U.S.

2025/1/31 TaiRx’s orally [...]

February 7th, 2025|News|

Company Announcement for Zelnite^®

2024/7/17 TaiRx, Inc. hereby declares that Zelnite® [...]

July 17th, 2024|News|

TaiRx‘s injectable product, Zelnite^®, has been approved by TFDA to add high dosage and change drug labeling

2024/5/9 In 2018, TaiRx received approval from [...]

May 9th, 2024|News|

TaiRx’s sodium selenite pentahydrate—SelenOne^®—earned the Symbol of National Quality (SNQ) in 2022 for its affirmed safety and quality for use as a food additive.

2022/12/23 In December [...]

January 12th, 2023|News|

Mr. Andrew Lin’s appointment as Chairman of TaiRx, Inc. is effective as of December 9, 2020.

2020/12/9 Andrew Lin [...]

December 9th, 2020|News|